文献速递胸部肿瘤放疗乳腺癌放疗

乳腺癌、肺癌和淋巴瘤当代胸部放疗后心血管生物标志物的早期变化

Early Changes in Cardiovascular Biomarkers with Contemporary Thoracic Radiation Therapy for Breast Cancer, Lung Cancer, and Lymphoma.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-11-14

前瞻性纵向研究纳入87例接受光子或质子胸部放疗的乳腺癌、肺癌或纵隔淋巴瘤患者,检测放疗前后心血管生物标志物。肺癌/纵隔淋巴瘤组胎盘生长因子和生长分化因子15显著升高,且与平均心脏剂量、V5和V30相关;乳腺癌组无显著变化。生物标志物变化与超声心动图心功能指标变化无显著关联。

要点

  • 乳腺癌患者放疗前后心血管生物标志物无显著升高。
  • 肺癌/纵隔淋巴瘤患者胎盘生长因子和生长分化因子15显著升高。
  • 平均心脏剂量、V5和V30与放疗后胎盘生长因子和生长分化因子15水平显著相关。

核心结论

  • 当代胸部放疗可引起血管和炎症生物标志物的急性异常,且与放射剂量-体积参数相关,尤其在肺癌和纵隔淋巴瘤中。
  • 需要长期随访研究以确定这些变化对显性心脏病发展的影响。

研究设计与样本

  • 前瞻性纵向研究,纳入87例接受光子或质子胸部放疗的乳腺癌、肺癌或纵隔淋巴瘤患者。
  • 放疗前和放疗完成后(中位20天,四分位距1-35天)采集血样,检测高敏心肌肌钙蛋白T、N末端B型利钠肽原、胎盘生长因子和生长分化因子15。
  • 采用多变量线性回归模型评估平均心脏剂量、V5和V30与生物标志物水平的关联,以及超声心动图心功能指标与生物标志物水平的关联。
  • 分析分为乳腺癌单独组和肺癌与淋巴瘤合并组。

主要发现

  • 平均心脏剂量中位数(四分位距):乳腺癌患者(n=60)为1.3 Gy(0.9-2.4),纵隔淋巴瘤患者(n=14)为6.8 Gy(5.4-10.2),肺癌患者(n=13)为8.4 Gy(6.7-16.1)(P < .001)。
  • 乳腺癌患者放疗前后生物标志物水平无显著升高。
  • 肺癌/淋巴瘤患者胎盘生长因子从放疗前中位数(四分位距)20 ng/L(16-26)升高至放疗后22 ng/L(16-30)(P = .005)。
  • 肺癌/淋巴瘤患者生长分化因子15从放疗前1171 ng/L(755-2493)升高至放疗后1887 ng/L(903-3763)(P = .006)。
  • 在多变量模型中,平均心脏剂量、V5和V30与放疗后胎盘生长因子和生长分化因子15水平显著相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要长期随访研究以确定这些变化对显性心脏病发展的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We characterized the early changes in cardiovascular biomarkers with contemporary thoracic radiation therapy (RT) and evaluated their associations with radiation dose-volume metrics including mean heart dose (MHD), V5, and V30. METHODS AND MATERIALS: In a prospective longitudinal study of 87 patients with breast cancer, lung cancer, or mediastinal lymphoma treated with photon or proton thoracic RT, blood samples were obtained pre-RT and after completion of RT (median, 20 days; interquartile range [IQR], 1-35). High-sensitivity cardiac troponin T, N-terminal pro-B-type natriuretic peptide, placental growth factor (PIGF), and growth differentiation factor 15 (GDF-15) were measured. Associations between MHD, V5 and V30, and biomarker levels and associations between echocardiography-derived measures of cardiac function and biomarker levels were assessed in multivariable linear regression models. Analyses were performed according to the following subgroups: (1) breast cancer alone and (2) lung cancer and lymphoma combined. RESULTS: The median (IQR) estimates of MHD ranged from 1.3 Gy (0.9-2.4) in breast cancer (n = 60) to 6.8 Gy (5.4-10.2) in mediastinal lymphoma (n = 14) and 8.4 Gy (6.7-16.1) in lung cancer (n = 13) patients (P < .001). There were no significant increases in biomarker levels from pre-RT to post-RT in breast cancer. In lung cancer/lymphoma, PIGF increased from a median (IQR) of 20 ng/L (16-26) to 22 ng/L (16-30) (P = .005), and GDF-15 increased from 1171 ng/L (755-2493) to 1887 ng/L (903-3763) (P = .006). MHD, V5, and V30 were significantly associated with post-RT PIGF and GDF-15 levels in multivariable models. Changes in biomarkers were not significantly associated with changes in echocardiography-derived measures of cardiac function. CONCLUSION: Contemporary thoracic RT induces acute abnormalities in vascular and inflammatory biomarkers that are associated with radiation dose-volume metrics, particularly in lung cancer and mediastinal lymphoma. Long-term follow-up studies are needed to determine the impact of these changes on the development of overt cardiac disease.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Demissei BG, Freedman G, Feigenberg SJ, et al. Early Changes in Cardiovascular Biomarkers with Contemporary Thoracic Radiation Therapy for Breast Cancer, Lung Cancer, and Lymphoma. Int J Radiat Oncol Biol Phys. 2018. PMID: 30445173. doi:10.1016/j.ijrobp.2018.11.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。